Walleye Capital
PTGX icon

Walleye Capital’s Protagonist Therapeutics PTGX Stock Holding History

Walleye Capital’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$123 Buy
+1
New +$104 ﹤0.01% 4638
2024
Q4 		– Sell
-105,335
Closed -$4.74M – 5418
2024
Q3 		$4.74M Buy
+105,335
New +$4.26M 0.01% 1218
2024
Q2 		– Sell
-134,114
Closed -$3.88M – 5919
2024
Q1 		$3.88M Sell
134,114
-51,312
-28% -$1.4M 0.01% 1491
2023
Q4 		$4.25M Buy
185,426
+51,610
+39% +$903K 0.01% 1209
2023
Q3 		$2.23M Buy
133,816
+81,155
+154% +$1.57M 0.01% 1651
2023
Q2 		$1.45M Sell
52,661
-74,709
-59% -$1.87M 0.01% 1550
2023
Q1 		$2.93M Sell
127,370
-396,932
-76% -$6.67M 0.04% 512
2022
Q4 		$5.72M Buy
524,302
+421,359
+409% +$3.55M 0.1% 238
2022
Q3 		$868K Sell
102,943
-154,414
-60% -$1.46M 0.02% 1080
2022
Q2 		$2.04M Buy
257,357
+223,967
+671% +$2.71M 0.06% 361
2022
Q1 		$791K Sell
33,390
-64,608
-66% -$1.82M 0.02% 748
2021
Q4 		$3.35M Buy
97,998
+87,882
+869% +$2.78M 0.1% 207
2021
Q3 		$179K Buy
+10,116
New +$431K 0.01% 1214

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Walleye Capital's PTGX Position: Q2 2026 in Review

Walleye Capital opened a new position in Protagonist Therapeutics (PTGX) in Q2 2026: 1 share worth $123. The stake represents ﹤0.01% of the portfolio and ranks #4638 among its holdings. This is a return to the name: Walleye Capital previously reported a position in PTGX as recently as Q3 2024.

Walleye Capital first reported a position in PTGX in Q3 2021 and has held it in 13 quarters since. The position peaked at $5.72M in Q4 2022. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Walleye Capital held 1 share of Protagonist Therapeutics worth $123 as of Q2 2026.
  • Protagonist Therapeutics was a new Walleye Capital position in Q2 2026.
  • Protagonist Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #4638 holding.
  • Walleye Capital first reported a position in Protagonist Therapeutics in Q3 2021 and has held it in 13 quarters since.
  • Walleye Capital's Protagonist Therapeutics position peaked at $5.72M in Q4 2022.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.